BiotechTube
CinDome Pharma

CinDome Pharma

Phase 3
Cambridge, United StatesFounded 2018cindome.com

CinDome Pharma is a specialized biotech advancing deudomperidone (CIN-102), a prokinetic and antiemetic designed to improve upon the safety profile of existing gastroparesis treatments. The company leverages the hub-and-spoke operational model of its parent, CinRx, for efficient clinical development. Its strategy targets the substantial market of 12-16 million symptomatic patients in the U.S. alone, where current options are limited to short-term use or carry significant safety warnings.

Market Cap
Private
Pipeline
—
Patents
—
Publications
—

Private Company

Funding information not available

AI Company Overview

CinDome Pharma is a specialized biotech advancing deudomperidone (CIN-102), a prokinetic and antiemetic designed to improve upon the safety profile of existing gastroparesis treatments. The company leverages the hub-and-spoke operational model of its parent, CinRx, for efficient clinical development. Its strategy targets the substantial market of 12-16 million symptomatic patients in the U.S. alone, where current options are limited to short-term use or carry significant safety warnings.

GastroenterologyMetabolic Disorders

Technology Platform

Focused molecular redesign platform aimed at improving the safety profile of known pharmacophores, specifically applied to creating a safer formulation of domperidone for chronic use.

Opportunities

CinDome has the opportunity to establish deudomperidone as the first FDA-approved, safe, and chronic oral therapy for a gastroparesis patient population exceeding 12 million in the U.S.
alone.
Success could also open doors for development in related gastrointestinal motility disorders.

Risk Factors

The company faces significant clinical trial risk as a single-asset entity, regulatory scrutiny over long-term cardiac safety, and future commercialization challenges dependent on its parent company's strategy or the need for a partnership.

Competitive Landscape

Main competitors are metoclopramide (limited by a black box warning) and domperidone (not FDA-approved for gastroparesis). CinDome's differentiation is the specific design of deudomperidone to mitigate the cardiac risks associated with domperidone, aiming for a chronic-use label.